Table 2.
Distribution of the study population according to the indications of allopurinol prescription.
| Indication | frequency | percentage |
|---|---|---|
| Not documented | 771 | 39.0 |
| Insignificant hyperuricemia | 768 | 38.8 |
| Significant hyperuricemia | 66 | 3.5 |
| Gouty arthritis (confirmed) | 30 | 1.6 |
| Gouty arthritis (not confirmed) | 111 | 5.6 |
| Uric acid stone | 5 | 0.2 |
| Recurrent calcium oxalate stone | 4 | 0.1 |
| Kidney stone (not analysed) | 105 | 5.2 |
| Malignancy | 117 | 5.9 |
| Haemolysis | 1 | 0.1 |
| Total | 1978 | 100.0 |
Marked hyperuricemia: males more than 13 mg/dL and females more than 10 mg/dL; insignificant hyperuricemia: more than 7.3 mg/dL in males and more than 6.1 in females.